Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies

• Published in: International journal of molecular sciences Vol. 25; no. 20; p. 11055
• Main Authors: Nammour, Helena M, Madrigal, Karla, Starling, Caroline T, Doan, Hung Q
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.10.2024; MDPI
• Subjects: Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Cancer; Cancer therapies; Carcinoma; Carcinoma, Merkel Cell - drug therapy; Carcinoma, Merkel Cell - pathology; Carcinoma, Merkel Cell - therapy; Care and treatment; Cell growth; Clinical trials; Development and progression; Health aspects; Humans; Immunotherapy; Kinases; Lanreotide; Ligands; Metastasis; Molecular Targeted Therapy - methods; Mutation; Pathogenesis; Protein Kinase Inhibitors - therapeutic use; Response rates; Review; Skin; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; Skin Neoplasms - therapy; Tumorigenesis; Tumors; Tyrosine; Vascular endothelial growth factor; receptor tyrosine kinase inhibitors; clinical trials; targeted therapies; Merkel cell carcinoma; somatostatin analogs
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms252011055

Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs), both of which have positively improved response rates and reduced tumor volumes upon application to treatment of MCC. The introduction of such targeted therapies into treatment protocols holds promise for more personalized care tailored towards patients of diverse subtypes, thereby improving outcomes and mitigating tumor burden, especially for treatment-resistant individuals. In this review, we characterize recent findings surrounding targeted treatments that have been applied to MCC and provide an overview of emerging perspectives on translatable options that can be further developed to offer additional therapeutic avenues for patients with the disease.